Effectiveness of paliperidone extended-release for patients with schizophrenia: Focus on subjective improvement

Human Psychopharmacology

Volumn 28, Issue 2, 2013, Pages 107-116

  Na, Kyoung Sae ^a   Kim, Chul Eung ^b   Kim, Yong Sik ^c,d   Lee, Jong Il ^c   Han, Wou Sang ^e   Kang, Ung Gu ^c   Park, Doo Heum ^f   Kim, Bongseog ^g   Jung, Han Yong ^a   Yoon, Jin Sang ^h   Lim, Se Won ⁱ  

^a Soonchunhyang University   (South Korea)

^b Inha University Hospital   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d Dongguk University College of Medicine   (South Korea)

^e Seoul Medical Center   (South Korea)

^f Konkuk University Hospital   (South Korea)

^g Inje University College of Medicine   (South Korea)

^h Chonnam National University Medical School   (South Korea)

ⁱ Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

effectiveness; paliperidone; schizophrenia; SCL 90 R; switching

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; OLANZAPINE; PALIPERIDONE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ABNORMAL LABORATORY RESULT; ADULT; AGED; AKATHISIA; AMENORRHEA; ANXIETY; ARTICLE; BODY WEIGHT; BRADYKINESIA; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; DAYTIME SOMNOLENCE; DEPRESSION; DIAGNOSTIC VALUE; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCLE RIGIDITY; NAUSEA; NIGHT SLEEP; OPEN STUDY; OUTCOME ASSESSMENT; PERSONAL MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SIDE EFFECT; SLEEP QUALITY; SOCIAL INTERACTION; SOCIAL PSYCHOLOGY; SOMNOLENCE; SYMPTOM ASSESSMENT; SYMPTOM CHECKLIST 90; TREMOR; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; WAIST CIRCUMFERENCE;

ADULT; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; ISOXAZOLES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PYRIMIDINES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84875684240     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.2284     Document Type: Article

References (49)

1. APA. 1994. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association (APA): Washington DC.
2. APA. 2000. Handbook of Psychiatric Measures. American Psychiatric Association: Washington, D.C.
3. Arakawa R, Ito H, Takano A, et al,. 2008. Dose-finding study of paliperidone ER based on striatal and extrastriatal dopamine D2 receptor occupancy in patients with schizophrenia. Psychopharmacology (Berl) 197: 229-235.
4. Crespo-Facorro B, Pelayo-Teran JM, Perez-Iglesias R, et al,. 2007. Predictors of acute treatment response in patients with a first episode of non-affective psychosis: sociodemographics, premorbid and clinical variables. J Psychiatr Res 41: 659-666.
5. Davidson M, Emsley R, Kramer M, et al,. 2007. Efficacy, safety and early response of paliperidone extended-release tablets (paliperidone ER): results of a 6-week, randomized, placebo-controlled study. Schizophr Res 93: 117-130.
6. Davis JM, Chen N, and, Glick ID,. 2003. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 60: 553-564.
7. Derogatis LR, Lipman RS, Covi L,. 1973. SCL-90: an outpatient psychiatric rating scale - preliminary report. Psychopharmacol Bull 9: 13-28.
8. Derogatis LR, Rickels K, Rock AF,. 1976. The SCL-90 and the MMPI: a step in the validation of a new self-report scale. Br J Psychiatry 128: 280-289.
9. Emsley R, Berwaerts J, Eerdekens M, et al,. 2008. Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies. Int Clin Psychopharmacol 23: 343-356.
10. Frantseva MV, Fitzgerald PB, Chen R, Moller B, Daigle M, Daskalakis ZJ,. 2008. Evidence for impaired long-term potentiation in schizophrenia and its relationship to motor skill learning. Cereb Cortex 18: 990-996.
11. Geddes J, Freemantle N, Harrison P, Bebbington P,. 2000. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321: 1371-1376.
12. George MS, Padberg F, Schlaepfer TE, et al,. 2009. Controversy: repetitive transcranial magnetic stimulation or transcranial direct current stimulation shows efficacy in treating psychiatric diseases (depression, mania, schizophrenia, obsessive-complusive disorder, panic, posttraumatic stress disorder). Brain Stimul 2: 14-21.
13. Gross G, Huber G, Klosterkotter J, Linz M,. 1987. Bonn Scale for the Assessment of Basic Symptoms (BSABS). Springer: Berlin.
14. Haro JM, Kamath SA, Ochoa S, et al,. 2003. The Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand Suppl: 16-23.
15. Inada T, Yagi G, Miura S,. 2002. Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol. Schizophr Res 57: 227-238.
16. Jackson HJ, Burgess PM, Minas IH, Joshua SD,. 1990. Psychometric properties of the Manchester scale. Acta Psychiatr Scand 81: 108-113.
17. Jones PB, Barnes TR, Davies L, et al,. 2006. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63: 1079-1087.
18. Kane J, Canas F, Kramer M, et al,. 2007. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 90: 147-161.
19. Karlsson P, Dencker E, Nyberg S, et al,. 2005. Pharmacokinetics and dopamine D2 and serotonin 5-HT2A receptor occupancy of paliperidone in healthy subjects. Eur Neuropsychopharmacol 15 Supplement 3:(0) S386.
20. Kay SR, Fiszbein A, Opler LA,. 1987. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-276.
21. Kay SR, Opler LA, Fiszbein A,. 2000. The Positive and Negative Syndrome Scale (PANSS) Manual. Multi-Health Systems Inc.: Toronto.
22. Kim JH, Kim KI,. 1984. The standardization study of Symptom Checklist-90-Revision in Korea III. Mental Health Res 2: 278-310.
23. Kim JH, Yoon YH,. 1985. Reliability and factorial invariance of Korean version of the Symptom Checklist-90-Revision. Mental Health Res 3: 166-172.
24. Kim Y, Sakamoto K, Sakamura Y, Kamo T, Kotorii N,. 1997. Subjective experience and related symptoms in schizophrenia. Compr Psychiatry 38: 49-55.
25. Kim JH, Jung HY, Kang UG, et al,. 2002. Metric characteristics of the drug-induced extrapyramidal symptoms scale (DIEPSS): a practical combined rating scale for drug-induced movement disorders. Mov Disord 17: 1354-1359.
26. Lambert M, Schimmelmann BG, Naber D, et al,. 2006. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatry 67: 1690-1697.
27. Lee JG, Seok JH, Lee JY, et al,. 2006. A validation study of the Korean-version of the personal and social performance scale. Korean J Psychopharmacol 17: 497-506.
28. Lieberman JA, Stroup TS, McEvoy JP, et al,. 2005. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353: 1209-1223.
29. Loas G, Yon V, Marechal V, Decle P,. 2011. Relationships between subjective or objective symptoms and mortality in schizophrenia: a prospective study on 310 schizophrenic patients with a median follow-up of 8.4 years. Psychiatry Res 185: 49-53.
30. Luthringer R, Staner L, Noel N, et al,. 2007. A double-blind, placebo-controlled, randomized study evaluating the effect of paliperidone extended-release tablets on sleep architecture in patients with schizophrenia. Int Clin Psychopharmacol 22: 299-308.
31. Manchanda R, Saupe R, Hirsch SR,. 1986. Comparison between the brief psychiatric rating scale and the Manchester scale for the rating of schizophrenic symptoms. Acta Psychiatr Scand 74: 563-568.
32. Marder SR, Glynn SM, Wirshing WC, et al,. 2003. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry 160: 1405-1412.
33. Marder SR, Kramer M, Ford L, et al,. 2007. Efficacy and safety of paliperidone extended-release tablets: results of a 6-week, randomized, placebo-controlled study. Biol Psychiatry 62: 1363-1370.
34. Mass R, Haasen C, Borgart EJ,. 2005. Abnormal subjective experiences of schizophrenia: evaluation of the Eppendorf schizophrenia inventory. Psychiatry Res 135: 91-101.
35. Modestin J, Hermann S, Endrass J,. 2007. Schizoidia in schizophrenia spectrum and personality disorders: role of dissociation. Psychiatry Res 153: 111-118.
36. Morosini PL, Magliano L, Brambilla L, Ugolini S, Pioli R,. 2000. Development, reliability and acceptability of a new version of the DSM-IV social and occupational functioning assessment scale (SOFAS) to assess routine social functioning. Acta Psychiatr Scand 101: 323-329.
37. Nasrallah H, Morosini P, Gagnon DD,. 2008. Reliability, validity and ability to detect change of the personal and social performance scale in patients with stable schizophrenia. Psychiatry Res 161: 213-224.
38. Patrick DL, Burns T, Morosini P, et al,. 2009. Reliability, validity and ability to detect change of the clinician-rated personal and social performance scale in patients with acute symptoms of schizophrenia. Curr Med Res Opin 25: 325-338.
39. Patrick DL, Burns T, Morosini P, Gagnon DD, Rothman M, Adriaenssen I,. 2010. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets. Clin Ther 32: 275-292.
40. Penn DL, Keefe RS, Davis SM, et al,. 2009. The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. Schizophr Res 115: 17-23.
41. Rauter UK, Leonard CE, Swett CP,. 1996. SCL-90-R factor structure in an acute, involuntary, adult psychiatric inpatient sample. J Clin Psychol 52: 625-629.
42. Schennach-Wolff R, Jager M, Mayr A, et al,. 2011. Predictors of response and remission in the acute treatment of first-episode schizophrenia patients - is it all about early response? Eur Neuropsychopharmacol 21: 370-378.
43. Schultze-Lutter F,. 2009. Subjective symptoms of schizophrenia in research and the clinic: the basic symptom concept. Schizophr Bull 35: 5-8.
44. Seeman P,. 2005. An update of fast-off dopamine D2 atypical antipsychotics. Am J Psychiatry 162:(10) 1984-1985.
45. Skodlar B, Tomori M, Parnas J,. 2008. Subjective experience and suicidal ideation in schizophrenia. Compr Psychiatry 49: 482-488.
46. Süllwold L,. 1986. Frankfurter Beschwerde-Fragebogen (3). Springer: Berlin.
47. Vogel M, Spitzer C, Barnow S, Freyberger HJ, Grabe HJ,. 2006. The role of trauma and PTSD-related symptoms for dissociation and psychopathological distress in inpatients with schizophrenia. Psychopathology 39: 236-242.
48. Vothknecht S, Schoevers RA, de Haan L,. 2011. Subjective well-being in schizophrenia as measured with the subjective well-being under neuroleptic treatment scale: a review. Aust N Z J Psychiatry 45: 182-192.
49. Yoon KS, Park TW, Yang JC, et al,. 2012. Different safety profiles of risperidone and paliperidone extended-release: a double-blind, placebo-controlled trial with healthy volunteers. Hum Psychopharmacol 27: 305-314.